Tonix Pharmaceuticals Holding Corp. is a fully integrated, commercial-stage biopharmaceutical company focused on developing, licensing, and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its primary emphasis is on central nervous system (CNS) disorders, including fibromyalgia and major depressive disorder, addressed by product candidates like TNX-102 SL, a sublingual cyclobenzaprine HCl tablet branded as TONMYA, now available by prescription as the first new FDA-approved fibromyalgia treatment in over 15 years. The company also markets Zembrace SymTouch and Tosymra for acute migraine treatment in adults. In immunology, it advances biologics such as TNX-1500, a humanized monoclonal antibody targeting CD40-ligand for organ transplant rejection, autoimmunity, and cancer. Additional pipelines cover infectious diseases like mpox and Lyme disease prevention with TNX-801 and TNX-4800, respectively, rare diseases including Prader-Willi Syndrome via TNX-2900, and other areas. Founded in 2007 and headquartered in Chatham, New Jersey, Tonix Pharmaceuticals Holding Corp. operates in the biotechnology sector, targeting unmet medical needs across multiple therapeutic domains.